Pediatric Acute Toxic Leukoencephalopathy: Prediction of the Clinical Outcome by FLAIR and DWI for Various Etiologies

References

1. 1.↵
   1. Rimkus Cde M,
   2. Andrade CS,
   3. Leite Cda C, et al

   . Toxic leukoencephalopathies, including drug, medication, environmental, and radiation-induced encephalopathic syndromes. Semin Ultrasound CT MR 2014;35:97–117 doi:10.1053/j.sult.2013.09.005 pmid:24745887

   CrossRefPubMed
2. 2.↵
   1. Koksel Y,
   2. Ozutemiz C,
   3. Rykken J, et al

   . “CHOICES”: an acronym to aid in delineating potential causes of non-metabolic, non-infectious acute toxic leukoencephalopathy. Eur J Radiol Open 2019;6:243–57 doi:10.1016/j.ejro.2019.06.005 pmid:31309133

   CrossRefPubMed
3. 3.↵
   1. Beitinjaneh A,
   2. McKinney AM,
   3. Cao Q, et al

   . Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:300–08 doi:10.1016/j.bbmt.2010.04.003 pmid:20399878

   CrossRefPubMed
4. 4.↵
   1. Luckman J,
   2. Zahavi A,
   3. Efrati S, et al

   . Difficulty in distinguishing posterior reversible encephalopathy syndrome, hypoxic-ischemic insult, and acute toxic leukoencephalopathy in children. Neuropediatrics 2016;47:33–38 doi:10.1055/s-0035-1569154 pmid:26645328

   CrossRefPubMed
5. 5.↵
   1. Kontzialis M,
   2. Huisman T

   . Toxic-metabolic neurologic disorders in children: a neuroimaging review. J Neuroimaging 2018;28:587–95 doi:10.1111/jon.12551 pmid:30066477

   CrossRefPubMed
6. 6.↵
   1. De Cauwer H,
   2. De Wolf P,
   3. Couvreur F, et al

   . An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 2009;109:40–41 pmid:19402572

   PubMed
7. 7.↵
   1. Abeyakoon O,
   2. Batty R,
   3. Mordekar S, et al

   . The encephalopathic child. Neuroradiol J 2011;24:483–502 doi:10.1177/197140091102400403 pmid:24059705

   CrossRefPubMed
8. 8.↵
   1. Kumar Y,
   2. Drumsta D,
   3. Mangla M, et al

   . Toxins in brain! magnetic resonance (MR) imaging of toxic leukoencephalopathy: a pictorial essay. Pol J Radiol 2017;82:311–19 doi:10.12659/PJR.901791 pmid:28656068

   CrossRefPubMed
9. 9.↵
   1. Okumura A,
   2. Kidokoro H,
   3. Tsuji T, et al

   . Differences of clinical manifestations according to the patterns of brain lesions in acute encephalopathy with reduced diffusion in the bilateral hemispheres. AJNR Am J Neuroradiol 2009;30:825–30 doi:10.3174/ajnr.A1431 pmid:19131408

   Abstract/FREE Full Text
10. 10.↵
    1. Ozutemiz C,
    2. Roshan SK,
    3. Kroll NJ, et al

    . Acute toxic leukoencephalopathy: etiologies, imaging findings, and outcomes in 101 patients. AJNR Am J Neuroradiol 2019;40:267–75 doi:10.3174/ajnr.A5947 pmid:30679224

    Abstract/FREE Full Text
11. 11.↵
    1. Tsubouchi Y,
    2. Itamura S,
    3. Saito Y, et al

    . Use of high b value diffusion-weighted magnetic resonance imaging in acute encephalopathy/encephalitis during childhood. Brain Dev 2018;40:116–25 doi:10.1016/j.braindev.2017.07.012 pmid:28838686

    CrossRefPubMed
12. 12.↵
    1. Le Bras A,
    2. Proisy M,
    3. Kuchenbuch M, et al

    . Reversible lesions of the corpus callosum with initially restricted diffusion in a series of Caucasian children. Pediatr Radiol 2018;48:999–1007 doi:10.1007/s00247-018-4124-x pmid:29666887

    CrossRefPubMed
13. 13.↵
    1. McKinney AM,
    2. Short J,
    3. Truwit CL, et al

    . Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007;189:904–12 doi:10.2214/AJR.07.2024 pmid:17885064

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Casey SO,
    2. Sampaio RC,
    3. Michel E, et al

    . Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000;21:1199–1206 pmid:10954269

    Abstract/FREE Full Text
15. 15.↵
    1. McKinney AM,
    2. Kieffer SA,
    3. Paylor RT, et al

    . Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 2009;193:192–206 doi:10.2214/AJR.08.1176 pmid:19542414

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Rana L,
    2. Sood D,
    3. Chauhan R, et al

    . MR imaging of hypoxic ischemic encephalopathy: distribution patterns and ADC value correlations. Eur J Radiol Open 2018;5:215–20 doi:10.1016/j.ejro.2018.08.001 pmid:30480058

    CrossRefPubMed
17. 17.↵
    1. Liauw L,
    2. van Wezel-Meijler G,
    3. Veen S, et al

    . Do apparent diffusion coefficient measurements predict outcome in children with neonatal hypoxic-ischemic encephalopathy? AJNR Am J Neuroradiol 2009;30:264–70 doi:10.3174/ajnr.A1318 pmid:18842756

    Abstract/FREE Full Text
18. 18.↵
    1. Chang KH,
    2. Han MH,
    3. Kim HS, et al

    . Delayed encephalopathy after acute carbon monoxide intoxication: MR imaging features and distribution of cerebral white matter lesions. Radiology 1992;184:117–22 doi:10.1148/radiology.184.1.1609067 pmid:1609067

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Crombe A,
    2. Alberti N,
    3. Gilles M, et al

    . Extensive acute toxic leukoencephalopathy induced by fludarabine: two months follow-up on brain MRI. J Neuroradiol 2015;42:127–30 doi:10.1016/j.neurad.2014.08.001 pmid:25454396

    CrossRefPubMed
20. 20.↵
    1. Trivedi SB,
    2. Vesoulis ZA,
    3. Rao R, et al

    . A validated clinical MRI injury scoring system in neonatal hypoxic-ischemic encephalopathy. Pediatr Radiol 2017;47:1491–99 doi:10.1007/s00247-017-3893-y pmid:28623417

    CrossRefPubMed
21. 21.↵
    1. Lee MS,
    2. McKinney AM,
    3. Brace JR, et al

    . Clinical and imaging features of fludarabine neurotoxicity. J Neuroophthalmol 2010;30:37–41 doi:10.1097/WNO.0b013e3181ce8087 pmid:20182205

    CrossRefPubMed
22. 22.↵
    1. Shibutani M,
    2. Okeda R

    . Experimental study on subacute neurotoxicity of methotrexate in cats. Acta Neuropathol 1989;78:291–300 doi:10.1007/BF00687759 pmid:2763801

    CrossRefPubMed
23. 23.↵
    1. Wilasrusmee C,
    2. Da Silva M,
    3. Singh B, et al

    . Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction. Clin Transplant 2003;17(Suppl 9):6–12 doi:10.1034/j.1399-0012.17.s9.1.x pmid:12795661

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Jakkani RK,
    2. Krishna Reddy GV,
    3. Anasuri S, et al

    . MRI findings in methotrexate-induced acute toxic leukoencephalopathy. Neurol India 2017;65:1439–40 doi:10.4103/0028-3886.217945 pmid:29133739

    CrossRefPubMed
25. 25.↵
    1. Cerase A,
    2. Leonini S,
    3. Bellini M, et al

    . Methadone-induced toxic leukoencephalopathy: diagnosis and follow-up by magnetic resonance imaging including diffusion-weighted imaging and apparent diffusion coefficient maps. J Neuroimaging 2011;21:283–86 doi:10.1111/j.1552-6569.2010.00530.x pmid:20977538

    CrossRefPubMed
26. 26.↵
    1. Capizzano AA,
    2. Sanchez A,
    3. Moritani T, et al

    . Hyperammonemic encephalopathy: time course of MRI diffusion changes. Neurology 2012;78:600–01 doi:10.1212/WNL.0b013e318247ccd1 pmid:22351798

    FREE Full Text
27. 27.↵
    1. Hayakawa K,
    2. Koshino S,
    3. Tanda K, et al

    . Diffusion pseudonormalization and clinical outcome in term neonates with hypoxic-ischemic encephalopathy. Pediatr Radiol 2018;48:865–74 doi:10.1007/s00247-018-4094-z pmid:29417166

    CrossRefPubMed
28. 28.↵
    1. Barkovich AJ

    . Concepts of myelin and myelination in neuroradiology. AJNR Am J Neuroradiol 2000;21:1099–09 pmid:10871022

    FREE Full Text
29. 29.↵
    1. Barkovich AJ,
    2. Miller SP,
    3. Bartha A, et al

    . MR imaging, MR spectroscopy, and diffusion tensor imaging of sequential studies in neonates with encephalopathy. AJNR Am J Neuroradiol 2006;27:533–47 pmid:16551990

    Abstract/FREE Full Text